Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
34 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
AlphaVax, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AlphaVax, Inc. - Product Pipeline Review - 2014', provides an overview of the AlphaVax, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of AlphaVax, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of AlphaVax, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of AlphaVax, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the AlphaVax, Inc.'s pipeline products Reasons to buy - Evaluate AlphaVax, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of AlphaVax, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the AlphaVax, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of AlphaVax, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of AlphaVax, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of AlphaVax, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 AlphaVax, Inc. Snapshot 5 AlphaVax, Inc. Overview 5 Key Information 5 Key Facts 5 AlphaVax, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 AlphaVax, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 AlphaVax, Inc. - Pipeline Products Glance 11 AlphaVax, Inc. - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 AlphaVax, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 AlphaVax, Inc. - Drug Profiles 13 AVX-101 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 AVX-502 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 AVX-701 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 AVX-901 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 AVX-601 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Botulinum Toxin Vaccine 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Equine Encephalitis Vaccine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Filovirus Vaccine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 herpes simplex vaccine [HSV-2] 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 HIV vaccine (Multivalent) 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Pandemic Influenza Vaccine 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 RSV Vaccine 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 SARS Vaccine 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 smallpox vaccine 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 AlphaVax, Inc. - Pipeline Analysis 28 AlphaVax, Inc. - Pipeline Products by Target 28 AlphaVax, Inc. - Pipeline Products by Route of Administration 29 AlphaVax, Inc. - Pipeline Products by Molecule Type 30 AlphaVax, Inc. - Recent Pipeline Updates 31 AlphaVax, Inc. - Locations And Subsidiaries 32 Head Office 32 Appendix 33 Methodology 33 Coverage 33 Secondary Research 33 Primary Research 33 Expert Panel Validation 33 Contact Us 34 Disclaimer 34
List of Tables AlphaVax, Inc., Key Information 5 AlphaVax, Inc., Key Facts 5 AlphaVax, Inc. - Pipeline by Indication, 2014 8 AlphaVax, Inc. - Pipeline by Stage of Development, 2014 9 AlphaVax, Inc. - Monotherapy Products in Pipeline, 2014 10 AlphaVax, Inc. - Phase I, 2014 11 AlphaVax, Inc. - Preclinical, 2014 12 AlphaVax, Inc. - Pipeline by Target, 2014 28 AlphaVax, Inc. - Pipeline by Route of Administration, 2014 29 AlphaVax, Inc. - Pipeline by Molecule Type, 2014 30 AlphaVax, Inc. - Recent Pipeline Updates, 2014 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.